https://z-lehd-fmkinhibitor.co....m/bioaccumulation-an
Cancer heterogeneity represents a possible obstacle for the analysis of predicitive biomarkers. MSI was reported in pancreatic cancer, but data in the feasible extent of intratumoral heterogeneity are lacking. Ways to study MSI heterogeneity in pancreatic disease, a tissue microarray (TMA) comprising 597 tumors had been screened by immunohistochemistry with antibodies for the mismatch fix (MMR) proteins MLH1, PMS2, MSH2, and MSH6. Leads to six su
Like
Comment
Share
